Blood Pressure Lowering Effect of Supplementation With Korea Red Ginseng Associated With Reductions in Circulating Lp-PLA2 Activity and Lysophospatidylcholines and an Increase in Dihydrobiopterin in Prehypertensive Subjects
Status and phase
Conditions
Treatments
Details and patient eligibility
About
This study evaluated effects of red ginseng consumption on blood pressure (BP) and fasting plasma metabolomes.
Full description
A randomized, double-blind, placebo-controlled study was conducted on nonobese, nondiabetic and prehypertensive subjects. Over a 12 week test period, the red ginseng group (n=31) consumed 10 capsules (total 5g) daily containing red ginseng, while the placebo group (n=31) consumed the same product without red ginseng. Fasting plasma metabolomes were profiled using UPLC-LTQ-Orbitrap mass spectrometry.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- nondiabetic, nonobese and prehypertensive subjects with blood pressures ranging 120 - 139 mmHg (systolic) or 80-89 mmHg (diastolic) were enrolled in this study.
Exclusion criteria
- exclusion criteria included previous diagnosed clinical hypertension
- self-reported use of antihypertensive medication
- abnormal liver or renal function
- history of cardiovascular disease
- kidney disease
- cancer
- thyroid or pituitary disease or any other serious life-threatening illness that required regular medical treatment
- we also excluded women who were pregnant, breast feeding or intending to become pregnant during the time of study.
Trial design
Primary purpose
Allocation
Interventional model
Masking
62 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal